Progression patterns under BRAF inhibitor treatment and treatment beyond progression in patients with metastatic melanoma.

about

Biomarkers for Clinical Benefit of Immune Checkpoint Inhibitor Treatment-A Review From the Melanoma Perspective and Beyond

P2860

Q56891609-A87C7B65-C950-448E-A787-48078488862C

P2860

Progression patterns under BRAF inhibitor treatment and treatment beyond progression in patients with metastatic melanoma.

Item

http://www.wikidata.org/entity/Q47268734

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Progression patterns under BRA ...... ents with metastatic melanoma.

@en

Progression patterns under BRA ...... ents with metastatic melanoma.

@nl

type

Item

label

Progression patterns under BRA ...... ents with metastatic melanoma.

@en

Progression patterns under BRA ...... ents with metastatic melanoma.

@nl

prefLabel

Progression patterns under BRA ...... ents with metastatic melanoma.

@en

Progression patterns under BRA ...... ents with metastatic melanoma.

@nl

P1476

Progression patterns under BRA ...... ients with metastatic melanoma

@en

P2093

Alla Slynko

http://www.w3.org/2001/XMLSchema#string

Benjamin Weide

http://www.w3.org/2001/XMLSchema#string

Carmen Loquai

http://www.w3.org/2001/XMLSchema#string

Carolin Bender

http://www.w3.org/2001/XMLSchema#string

German Dermatooncology Group (DeCOG/ADO)

http://www.w3.org/2001/XMLSchema#string

Lisa Zimmer

http://www.w3.org/2001/XMLSchema#string

Ralf Gutzmer

http://www.w3.org/2001/XMLSchema#string

Selma Ugurel

http://www.w3.org/2001/XMLSchema#string

P2860

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

Combined vemurafenib and cobimetinib in BRAF-mutated melanoma.

Improved overall survival in melanoma with combined dabrafenib and trametinib.

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

Final version of 2009 AJCC melanoma staging and classification

Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian cohort of the ipilimumab expanded access program.

Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials.

The nature and management of metastatic melanoma after progression on BRAF inhibitors: effects of extended BRAF inhibition.

P304

95-104

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CAM4.1267

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Kristina Buder-Bakhaya

Jessica C Hassel

P577

2017-12-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29266761

http://www.w3.org/2001/XMLSchema#string

P932

5773979

http://www.w3.org/2001/XMLSchema#string

Progression patterns under BRAF inhibitor treatment and treatment beyond progression in patients with metastatic melanoma.

about

P2860

P2860

Progression patterns under BRAF inhibitor treatment and treatment beyond progression in patients with metastatic melanoma.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932